Author/Authors :
Mueller-Lenke, Nicole University Hospital Basel, Switzerland , Buerkle, Gerd Herz-Zentrum Bad Krozingen, Germany , Klima, Theresia University Hospital Basel, Switzerland , Breidthardt, Tobias University Hospital Basel, Switzerland , Buettner, Heinz J. Herz-Zentrum Bad Krozingen, Germany , Mueller, Christian University Hospital Basel, Switzerland , Mueller, Christian Herz-Zentrum Bad Krozingen, Germany
Abstract :
Objective: The present study was performed to determine the effect of combined intravenous and oral volume supplementation on the incidence of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention (PCI). Subjects and Methods: Consecutive patients (n = 958) receiving iomeprol 350 during PCI were evaluated prospectively for the development of CIN. All patients received protocol-defined intravenous and oral volume supplementation. CIN was defined as an increase in serum creatinine of at least 44 μmol/l within 48 h. Results: Of the 958 patients enrolled in the study, 147 (15%) were diabetic and 107 (11%) had stage III renal disease. The average baseline glomerular filtration rate was 88 ± 25 ml/min/1.73 m2. During the intervention an average of 238 ± 86 ml of contrast medium was administered. CIN developed in 13 of 958 (1.4%; 95% confidence interval 0.6–2.1%) patients. The incidence of CIN was low even in predefined risk subgroups (women: 2.4%, diabetics: 2.7%, patients with stage III kidney disease: 6.5%). Conclusions: The incidence of CIN is low when preprocedural fluid volume supplementation is used.
